NCT07241039
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07241039
Title A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors AbbVie
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | ISR | CAN

Facility Status City State Zip Country Details
City Of Hope Comprehensive Cancer Center /ID# 276550 RECRUITING Duarte California 91030 United States Details
City of Hope - Orange County Lennar Foundation Cancer Center /ID# 278432 RECRUITING Irvine California 92618 United States Details
University of Chicago Medical Center /ID# 276638 RECRUITING Chicago Illinois 60637 United States Details
START Midwest /ID# 272505 RECRUITING Grand Rapids Michigan 49546 United States Details
Carolina BioOncology Institute /ID# 272380 RECRUITING Huntersville North Carolina 28078 United States Details
Next Oncology - Irving /ID# 276659 RECRUITING Irving Texas 75039 United States Details
Princess Margaret Cancer Centre /ID# 276852 RECRUITING Toronto Ontario M5G 2M9 Canada Details
The Chaim Sheba Medical Center /ID# 276798 RECRUITING Ramat Gan Tel Aviv 5265601 Israel Details
Rambam Health Care Campus- Haifa /ID# 276799 RECRUITING Haifa 3109601 Israel Details
Hadassah Medical Center-Hebrew University /ID# 276800 RECRUITING Jerusalem 91120 Israel Details
National Cancer Center Hospital East /ID# 276585 RECRUITING Kashiwa-shi Chiba 277-8577 Japan Details
Kansai Medical University Hospital /ID# 276586 RECRUITING Hirakata-shi Osaka 573-1191 Japan Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field